Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer

被引:63
作者
Rubin, BP
Skarin, AT
Pisick, E
Rizk, M
Salgia, R
机构
[1] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Div Adult Oncol, Boston, MA 02115 USA
[4] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
关键词
carcinoma; CK7; CK20; cytokeratins; lung cancer; unknown primary;
D O I
10.1097/00008469-200102000-00009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic carcinoma of unknown primary is a common problem, accounting for up to 10-15% of all solid tumours at presentation. Proper identification of the site of origin has prognostic and therapeutic significance. Prior immunohistochemical methods to identify the site of origin have been useful in a limited number of cases. Differential cytokeratin staining may be useful in this setting, particularly in identifying metastases from lung cancer. We have identified 144 cases of metastatic carcinoma of unknown primary to bone, lung or liver at Brigham and Women's Hospital between 1 January 1997 and 1 July 1998, Cytokeratin (CK) 7 and CK20 were used in 75 of these cases to narrow down the possible sites of the primary tumours. All of these cases were ambiguous as to the site of the primary tumour. Forty-five cases were CK7 + /CK20-, 15 cases were CK7-/CK20-, 9 cases were CK7-/CK20 + and 6 cases were CK7 + /CK20 +. Three of the cases were selected for detailed presentation and discussion as well as a discussion of the pertinent literature. Overall, the CK7 + /CK20- phenotype favours a lung primary, the CK7 + /CK20 + phenotype strongly favours transitional cells (urothelial) carcinoma, the CK7-/CK20 + phenotype favours colorectal carcinoma, while the CK7-/ CK20- profile is not helpful. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:77 / 82
页数:6
相关论文
共 36 条
[1]   Cytokeratin profile of extrahepatic pancreaticobiliary epithelia and their carcinomas - Diagnostic application [J].
Alexander, J ;
Krishnamurthy, S ;
Kovacs, D ;
Dayal, Y .
APPLIED IMMUNOHISTOCHEMISTRY, 1997, 5 (04) :216-222
[3]   THE APPLICABILITY OF A KERATIN 7 MONOCLONAL-ANTIBODY IN ROUTINELY PAPANICOLAOU-STAINED CYTOLOGIC SPECIMENS FOR THE DIFFERENTIAL-DIAGNOSIS OF CARCINOMAS [J].
BAARS, JH ;
DERUIJTER, JLM ;
SMEDTS, F ;
VANNIEKERK, CC ;
POELS, LG ;
SELDENRIJK, CA ;
RAMAEKERS, FCS .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1994, 101 (03) :257-261
[4]   DIAGNOSIS OF PRIMARY THYROID-CARCINOMA BY IMMUNOHISTOLOGICAL DEMONSTRATION OF THYROGLOBULIN [J].
BURT, A ;
GOUDIE, RB .
HISTOPATHOLOGY, 1979, 3 (04) :279-286
[5]   A fault-tolerant triple triangular mesh protocol for distributed mutual exclusion [J].
Chang, YI ;
Chang, YJ .
JOURNAL OF THE CHINESE INSTITUTE OF ENGINEERS, 1997, 20 (01) :21-26
[6]  
COOPER D, 1985, LAB INVEST, V52, P243
[7]   METASTATIC OVARIAN-CARCINOMA OF LARGE INTESTINAL ORIGIN SIMULATING PRIMARY OVARIAN-CARCINOMA - A CLINICOPATHOLOGICAL STUDY OF 25 CASES [J].
DAYA, D ;
NAZERALI, L ;
FRANK, GL .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 97 (06) :751-758
[8]   TUMOR-MARKER IMMUNOREACTIVITY IN ADENOCARCINOMA [J].
ELLIS, IO ;
HITCHCOCK, A .
JOURNAL OF CLINICAL PATHOLOGY, 1988, 41 (10) :1064-1067
[9]  
Erlandson RA, 1994, DIAGNOSTIC TRANSMISS
[10]  
FLINT A, 1992, ARCH PATHOL LAB MED, V116, P39